These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28810322)

  • 41. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
    Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
    Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeted chronic myeloid leukemia therapy: seeking a cure.
    Fausel C
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase].
    Chen YL; Wang L; Yan GL; Yang ZZ; Huang ZP; Zhang YS; Zhao Z; Wan CC; Bao Y; Xiang H; Yin H; Chen LF; Xiong YY; Meng L; Li WM
    Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):98-104. PubMed ID: 30831623
    [No Abstract]   [Full Text] [Related]  

  • 45. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes.
    Tian J; Song YP; Zhang GC; Wang SF; Chu XX; Chai Y; Wang CL; He AL; Zhang F; Shen XL; Zhang WH; Yang LH; Nie DN; Wang DM; Zhu HL; Gao D; Lou SF; Zhou ZP; Su GH; Li Y; Lin JY; Shi QZ; Ouyang GF; Jing HM; Chen SJ; Li J; Mi JQ
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):189. PubMed ID: 38605258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of Survival of Patients with Chronic Myeloid Leukemia Treated with Imatinib in the Last 15 Years in Lebanon.
    Massoud M; Sakr R; Kerbage F; Makdissi J; Hawi J; Rached L; Nasr F; Chahine G
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S111-S115. PubMed ID: 28760296
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice.
    Awidi A; Abbasi S; Alrabi K; Kheirallah KA
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e55-e61. PubMed ID: 28844599
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib].
    Huang XJ; Hu JD; Li JY; Jin J; Meng FY; Shen ZX; Liu T; Wu DP; Wang JM; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):889-95. PubMed ID: 23363742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety.
    Huang X; Jiang Q; Hu J; Li J; Jin J; Meng F; Shen Z; Liu T; Wu D; Wang J; Wang J
    Front Med; 2019 Jun; 13(3):344-353. PubMed ID: 30159669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia].
    Jiang Q; Zhao D; Jin J; Wu D; Meng F; Hu J; Liu B; DU X; Liu T; Li Y; Hou M; Han X; Shen Z; Ma J
    Zhonghua Xue Ye Xue Za Zhi; 2015 Aug; 36(8):651-5. PubMed ID: 26462633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Real-World Efficacy and Safety of China-Made Flumatinib Mesylate in the Treatment of Chronic Myeloid Leukemia in Chronic Phase].
    Li YY; Wang CL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):14-19. PubMed ID: 38387894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia.
    Chen Y; Yin H; Chen L; Xiong Y; Meng L; Guo J; Wang H; Li W
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e43-e49. PubMed ID: 31902734
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study.
    Dou X; Zheng F; Zhang L; Jin J; Zhang Y; Liu B; Meng L; Zhu X; Lu Z; Jia Y; Liu H; Lin H; Zhou L; Zhao X; Yang W; Sun H; Qian S; Ma H; Du X; Bai Q; Xu N; Meng F; Jia Z; Di H; Zhang L; Jiang Q
    Ann Hematol; 2021 Sep; 100(9):2215-2228. PubMed ID: 34089385
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.
    Ko PS; Yu YB; Liu YC; Wu YT; Hung MH; Gau JP; Liu CJ; Hsiao LT; Chen PM; Chiou TJ; Liu CY; Liu JH
    Curr Med Res Opin; 2017 Oct; 33(10):1737-1744. PubMed ID: 28715941
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
    de Lavallade H; Apperley JF; Khorashad JS; Milojkovic D; Reid AG; Bua M; Szydlo R; Olavarria E; Kaeda J; Goldman JM; Marin D
    J Clin Oncol; 2008 Jul; 26(20):3358-63. PubMed ID: 18519952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country.
    Medhi K; Raina V; Kumar L; Sharma A; Bakhshi S; Gupta R; Kumar R
    Leuk Lymphoma; 2010 Oct; 51(10):1850-4. PubMed ID: 20849386
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
    Gambacorti-Passerini C; Antolini L; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D'Emilio A; Stagno F; le Coutre P; Hurtado-Monroy R; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Puttini M; Jang E; Reiffers J; Piazza R; Valsecchi MG; Kim DW
    J Natl Cancer Inst; 2011 Apr; 103(7):553-61. PubMed ID: 21422402
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of medical insurance coverage and molecular monitoring frequency on outcomes in chronic myeloid leukemia: real-world evidence in China.
    Sheng G; Chen S; Zhang R; Miao M; Wu D; Tan SC; Liu C; Xiong T
    J Med Econ; 2017 Apr; 20(4):382-387. PubMed ID: 27937141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.